
The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts
Neuroendocrine Cancer Foundation
The Neuroendocrine Cancer Foundation Podcast is a monthly series where we interview neuroendocrine cancer experts on various NET topics. Each expert will answer the top 10 FAQs in their area of expertise. Whether a listener is newly diagnosed, a longtime NET survivor, or a family member or loved one, the Neuroendocrine Cancer Foundation Podcast serves as a tool to help anyone better understand neuroendocrine cancer. For more information, visit www.ncf.net/podcast.
All episodes
Best episodes
Seasons
Top 10 The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts Episodes
Goodpods has curated a list of the 10 best The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts episode by adding your comments to the episode page.

Episode 29: "Nutrition & Diet Considerations for NET" with Sina Teskey
The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts
01/15/24 • 45 min
NET dietician Sina Teskey from the Medical College of Wisconsin answers common questions about diet and nutrition raised among NET patients and caregivers. She addresses special diets, food restrictions, and whether sugar “feeds” cancer. Sina also speaks to diarrhea, and digestive enzymes and shares tips on how to maintain nutrition and weight.
MEET SINA TESKEY, RD, CD
Sina Teskey, RD, CD received her B.S. from the University of Wisconsin-Madison in 2006 and completed her dietetic internship at the University of Minnesota Medical College-Fairview in 2007. She has spent most of her career working with cancer and eating disorder patients. Sina practiced in the Twin Cities area for 10 years where she also spent time guest starring on a local TV show called Twin Cities Live to share nutrition advice.
She moved to Milwaukee and has worked at Froedtert Hospital and the Medical College of Wisconsin since 2018. Sina sees all patients with cancer but specializes in GI cancers and neuroendocrine tumor patients. When she’s not working, Sina is a mom to three kids and a Labrador retriever. She loves to cook and bring people together with food. Her youngest son was diagnosed with non-Hodgkin’s Lymphoma in 2019. His cancer journey gave insight into what having cancer means to a family and has impacted her practice profoundly. Her son Milo is now 7 years old and in remission.
TOP TEN QUESTIONS
- Is there a diet NET patients should follow? Are there foods NET patients should avoid? Some people say there are certain “trigger foods” to avoid. What CAN I eat?
- What diet is helpful after bowel surgery? What about pancreas surgery?
- Are there vitamins or supplements recommended for NET patients?
- What can NET patients do about diarrhea? What diet or medications might help?
- What can NET patients do if they struggle with a poor appetite?
- What can NET patients do if they are struggling to keep on or gain weight?
- What can NET patients do to stay hydrated?
- What are pancreatic enzymes and how are they taken? Who are they recommended for?
- What proteins can people take if they are vegetarian or vegan given soy may be a trigger for carcinoid syndrome?
- What do you think of alternative diets such as the keto diet or other “special diets?” Does sugar feed cancer? What about intermittent fasting?
For more information, visit
For more information, visit LACNETS.org.

Episode 19: "Beyond the Basics: The Pathology of NET"
The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts
03/15/23 • 60 min
Take a glimpse through the microscope and learn how pathology determines your NET diagnosis and guides treatment. How does one interpret differing Ki-67 results from the same specimen? Why might a patient have two different Ki-67 results from different specimens? How does pathology distinguish G3 well-differentiated NET from NEC? How does pathology help with NET tumors of unknown origin? NET pathologist Dr. Andrew M. Bellizzi from the University of Iowa sheds light on just how much information a tiny tissue sample may contain.
For more information, visit LACNETS.org.

NET Oncology with Dr. Jun Gong of Cedars-Sinai Medical Center
The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts
09/15/22 • 30 min
Is it okay for NET patients to take “statin” medications to lower cholesterol or SSRI medication for depression? How often should full body scans be done? NET oncologist Dr. Jun Gong of Cedars-Sinai Medical Center addresses ten common questions you might ask your NET oncologist along your NET journey. Listen now!
For more information, visit LACNETS.org.

Episode 38 - NEN Treatments: Focus on Liver-Directed Therapies (Part I: Overview and Ablative Techniques Including Histotripsy)
The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts
10/21/24 • 31 min
ABOUT THIS EPISODE
In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this first episode, he outlines the types of liver-directed therapies and elaborates on ablative techniques including the newest technique, histotripsy. Listen to a frank discussion of how histotripsy works, when it might be used, and what its current limitations are.
TOP TEN QUESTIONS ABOUT LIVER-DIRECTED THERAPY INCLUDING HISTOTRIPSY:
- What is liver-directed therapy? How does it work? Is this considered “surgery”? What is a surgery and what is a “procedure?”
- What are the types of liver-directed therapies used for neuroendocrine cancer?
- Which neuroendocrine cancers are they used for and when are they used? How do you decide who is a good candidate and if it will be effective?
- When are liver-directed therapies NOT used? Can someone who has had a Whipple undergo liver-directed therapy?
- What is the ablation zone? What is a heat sink effect?
- What is histotripsy? How does it work?
- When is histotripsy used (tumor grade, type of tumor - PNET/lung NET, size, number of tumor, location)? Can they be used for liver tumors even if there are tumors outside the liver?
- What are the limitations to histotripsy?
- What happens to the liver tissue after ablation? What are the results or success rates of patients being treated? Can histotripsy “cure” NET?
- How do you decide between the various types of liver-directed therapies?
MEET DR. OSMAN AHMED:
Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage.
In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology.
Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology.
Visit lacnets.org/podcast/38 for the podcast, transcript, and resources.
For more information, visit LACNETS.org.

Episode 33: Focus on Targeted Therapies
The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts
05/15/24 • 48 min
ABOUT THIS EPISODE
What are Targeted Therapies and how do they work? How and when would they be used in NETs? Dr. Scott Paulson from Baylor Cancer Center in Dallas discusses common questions and concerns about targeted therapies including side effects, dosing and treatment sequencing. Bonus: Dr. Paulson shares how we can learn from Harry Potter’s invisibility cloak in understanding treatment goals with NETs.
MEET DR. SCOTT PAULSON
Dr. Paulson is a medical oncologist and the medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center in Dallas, Texas. He also serves as the co-director of the Gastrointestinal Research Program for the Sarah Cannon Research Institute.
Dr. Paulson earned his medical doctorate at The University of Texas Southwestern Medical School. He took his residency and an internship in internal medicine at Brigham and Women's Hospital in Boston, Massachuests. His fellowship was completed in medical oncology at the University of California, San Francisco.
Dr. Paulson is active in clinical research focused on neuroendocrine tumors as well as cancers of the pancreas, liver, esophagus, stomach, and colon. Dr. Paulson is active in clinical research focused on neuroendocrine tumors as well as cancers of the pancreas, liver, esophagus, stomach, and colon. He currently is an investigator on a clinical trial studying nab-sirolimus, a mTOR inhibitor, which is a type of targeted therapy.
TOP TEN QUESTIONS ABOUT TARGETED THERAPIES FOR NETs:
1. What are targeted therapies? Are they considered chemotherapy? How do they work?
2. What are the different types of targeted therapies for NETs?
3. When and how are targeted therapies used?
4. What side effects might someone have when taking a targeted therapy?
a.Can targeted therapies affect blood sugars or cause diabetes?
b. Can targeted therapies cause one to be immunocompromised?
c. Can targeted therapies affect one’s blood counts?
5. What is the goal of treatment with targeted therapies? (Why would one take these drugs given the potential side effects? Can the side effects be managed?)
6. How do you decide which targeted therapy to recommend for a patient?
7. Can a NET patient take more than one drug in this category? Can the medications be stopped and restarted?
8. What is your approach with dosing?
9. What is your approach with monitoring? What and how often do people need blood work?
10. Does taking a targeted therapy preclude someone from getting another treatment in the future, such as Lutathera/PRRT, or a clinical trial of alpha PRRT?
BONUS: What are the latest advances in targeted therapy? What is the future of targeted therapies?
For more information, please visit https://www.lacnets.org/podcast/33.
For more information, visit LACNETS.org.

Episode 26: What to Know About Lung NETs
The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts
10/15/23 • 44 min
What are lung NETs? What is DIPNECH? How is lung NET similar or different from lung cancer? Dr. Vineeth Sukrithan from Ohio State University Comprehensive Cancer Center gives a comprehensive overview of lung NET and DIPNECH, including the work-up and treatment options. He also discusses open clinical trials and exciting advances in lung NET research on the horizon.
For more information, visit LACNETS.org/podcast/24.
For more information, visit LACNETS.org.
For more information, visit LACNETS.org.

The LACNETS Story
The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts
12/17/21 • 64 min
In this special episode, we share the history of LACNETS – the who, what, and when. We journey down memory lane with eight special guests from before the birth of LACNETS to where it is today. This episode is dedicated to Giovanna Joyce Imbesi, the LACNETS Founder, whose vision and dedication inspires us all. Listen now!
For more information, visit LACNETS.org.

Pheochromocytoma & Paraganglioma (PPGL) with Dr. Jaydira Del Rivero
The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts
08/15/22 • 67 min
In honor of Pheo Para Awareness Week, NET endocrinologist and medical oncologist Dr. Jaydira Del Rivero of the National Cancer Institute answers ten common questions about pheochromocytoma and paraganglioma (PPGL). Dr. Del Rivero defines PPGL and describes the unique symptoms, genetic testing, and treatment options for PPGL. Listen now!
Additional PPGL resources can be found here: www.lacnets.org/pheo-para-resources
For more information, visit LACNETS.org.

Episode 32: Focus on Somatostatin Analogues (SSAs)
The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts
04/30/24 • 53 min
How do SSAs work? Should all NET patients be on one? What are the side effects? Dr. Edward Wolin from Mount Sinai Health System answers several common questions about the current and future role of somatostatin analogues in NET treatment.
MEET Dr. EDWARD M. WOLIN
Professor of Medicine, Medical Oncology, Icahn School of Medicine Director, Center for Carcinoid and Neuroendocrine Tumors Tisch Cancer Institute, Mount Sinai Health System
Dr. Edward M. Wolin is an internationally renowned authority on neuroendocrine tumors. Dr. Wolin is the Director of the Center for Carcinoid and Neuroendocrine Tumors at the Tisch Cancer Institute at Mount Sinai and Professor of Medicine, Medical Oncology at the Icahn School of Medicine at Mount Sinai.
The multidisciplinary Center for Carcinoid and Neuroendocrine Tumors features a robust research program with clinical trials aimed at finding the most effective treatments, including immunotherapy, biologic agents, targeted radiation therapy, and new approaches in molecular imaging for diagnosis. Dr. Wolin has pioneered innovative therapies with novel somatostatin analogs, mTOR inhibitors, anti-angiogenic drugs, and peptide receptor radiotherapy.
Prior to joining Mount Sinai, Dr. Wolin was Director of the Neuroendocrine Tumor Program at Montefiore Einstein Cancer Center. Previously, he worked for more than two decades with Cedars-Sinai Medical Center in Los Angeles, where he founded and directed one of the largest Carcinoid and Neuroendocrine Tumor Programs in the country, and subsequently directed the Neuroendocrine Tumor Program at University of Kentucky. Dr. Wolin is also the Co-Medical Director for the Carcinoid Cancer Foundation and is on the Carcinoid Cancer Research Grants Scientific Review Committee for the American Association for Cancer Research. He has published in many prestigious journals, including the New England Journal of Medicine and Journal of Clinical Oncology, and is a reviewer for numerous journals, including Journal of Clinical Oncology, Molecular Cancer Therapeutics, Clinical Cancer Research, and The Lancet Oncology.
During Dr. Wolin’s two decades at Cedars-Sinai Medical Center in Los Angeles, he developed a close friendship with LACNETS founder Giovanna Joyce Imbesi. Dr. Wolin was instrumental in the co-founding and development of LACNETS. LACNETS has always been very dear to his heart and he cherishes and honors the memory of Giovanna.
Dr. Wolin earned his medical degree from Yale School of Medicine. He completed both his residency in internal medicine and fellowship in medical oncology at Stanford University Hospital. He was also a clinical fellow at the National Cancer Institute of the National Institutes of Health. Dr. Wolin is board certified in internal medicine and medical oncology.
TOP TEN QUESTIONS ABOUT SOMATOSTATIN ANALOGUES (SSAs) FOR NETS:
1. What are somatostatin analogues (SSAs)? How do they work?
2. When and how are SSAs used?
3. Which SSA should a patient be on? What is the difference? How do you decide?
4. How do you know if a SSA will be helpful? Should ALL NET patients be on a SSA?
5. What about patients whose tumors don’t “light up” on a DOTATATE scan?
6. How long can someone stay on a SSA?
7. What side effects may patients experience from the shot? What can patients do to prevent or manage these symptoms? How might it affect one’s day-to-day ability to work and function? Can I live a “normal life” while taking this medication?
8. If the tumor is growing does this mean the SSA did not work? Do you continue it when patients are treated with another treatment? When do you stop a SSA?
9. What is the future of SSAs? I heard there is a pill that is available in a clinical trial. Ca
For more information, visit LACNETS.org.

Episode 30: Bone & Brain Metastases in Neuroendocrine Cancer
The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts
02/15/24 • 43 min
When and how often do NETs spread to the bones or brain? How are they found? What is the treatment? Dr. Robert Ramirez of Vanderbilt University addresses concerns surrounding bone metastases (or “mets”) as well as rare brain metastases.
MEET DR. ROBERT RAMIREZ, DO, FACP
Dr. Robert Ramirez is a medical oncologist specializing in the treatment of thoracic and neuroendocrine malignancies and an Associate Professor of Medicine at Vanderbilt University Medical Center in Nashville, TN. He earned his medical degree from the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine. He completed an internal medicine residency at Cooper University Hospital in Camden, New Jersey. He then completed a hematology and medical oncology fellowship at the University of Tennessee Health Sciences Center in Memphis, Tennessee and served as chief fellow. He is a Fellow of the American College of Physicians, and a member of American Society of Clinical Oncology, the International Association for the Study of Lung Cancer (IASLC), and the North American Neuroendocrine Tumor Society (NANETS). He serves on the Board of Directors for NANETS as well as the Scientific Review and Research Committee.
His clinical and research interests include neuroendocrine tumors (NETs) and lung cancer. He has a specific interest in NETs of the lung ranging from diffuse idiopathic pulmonary neuroendocrine tumor cell hyperplasia (DIPNECH) and carcinoid tumors to small cell lung cancer and other high-grade neuroendocrine carcinomas. He is active in clinical trial design including investigator-initiated trials. He enjoys teaching residents and fellows and has multiple publications and given many lectures for the scientific community on the topics of NETs and lung cancers.
TOP TEN QUESTIONS
Bone mets:
1. When and how often do NETs spread to the bones?
2. Where in the bones are tumors? What does it mean when NETs spread to the bones? How does this compare to other cancers?
3. How are bone spots found and monitored? Should they be biopsied?
4. What is the treatment for bone mets? Should I have radiation? Would radiation limit my ability to get PRRT?
5. Should I be on bone strengthening medication? Am I at higher risk for fractures (or breaking my bones) if I have NETs in the bones?
6. Do bone mets respond to PRRT?
7. Does having bone mets put me at a higher risk of MDS?
Brain mets:
8. When and how often do NETs spread to the brain? Do all types of NETs have the potential to spread to the brain?
9. How are brain mets found and monitored? When should I suspect this?
10. How are brain mets treated? What does having brain mets mean for my life?
*Bonus: What final words of hope do you have for the neuroendocrine cancer community?
For more information, visit LACNETS.org.
Show more best episodes

Show more best episodes
FAQ
How many episodes does The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts have?
The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts currently has 45 episodes available.
What topics does The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts cover?
The podcast is about Net, Podcasts and Education.
What is the most popular episode on The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts?
The episode title 'Episode 33: Focus on Targeted Therapies' is the most popular.
What is the average episode length on The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts?
The average episode length on The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts is 48 minutes.
How often are episodes of The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts released?
Episodes of The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts are typically released every 30 days, 23 hours.
When was the first episode of The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts?
The first episode of The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts was released on Aug 23, 2021.
Show more FAQ

Show more FAQ